Pfizer (NYSE:PFE) has been given a $45.00 target price by stock analysts at Morgan Stanley in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price suggests a potential upside of 6.13% from the company’s previous close.

PFE has been the topic of several other reports. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Thursday, June 7th. They set an “overweight” rating and a $45.00 price target on the stock. Credit Suisse Group increased their price target on shares of Pfizer from $39.00 to $40.00 and gave the company a “neutral” rating in a research note on Wednesday, August 1st. Jefferies Financial Group reissued a “neutral” rating and set a $39.00 price target on shares of Pfizer in a research note on Monday, May 14th. BMO Capital Markets decreased their price target on shares of Pfizer from $43.00 to $42.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 2nd. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, July 31st. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $41.53.

PFE opened at $42.40 on Thursday. Pfizer has a one year low of $33.20 and a one year high of $42.77. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41. The company has a market cap of $250.97 billion, a PE ratio of 16.00, a P/E/G ratio of 2.04 and a beta of 0.96.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The business had revenue of $13.47 billion for the quarter, compared to analysts’ expectations of $13.30 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. Pfizer’s revenue was up 4.4% compared to the same quarter last year. equities analysts anticipate that Pfizer will post 2.99 EPS for the current fiscal year.

In other Pfizer news, CEO Ian C. Read sold 486,753 shares of the firm’s stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $37.36, for a total value of $18,185,092.08. Following the transaction, the chief executive officer now directly owns 1,145,693 shares of the company’s stock, valued at $42,803,090.48. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the transaction, the insider now directly owns 72,672 shares in the company, valued at $2,979,552. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 785,453 shares of company stock worth $29,937,357. Insiders own 0.06% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Pfizer by 2.8% during the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after purchasing an additional 12,183,218 shares in the last quarter. Mackenzie Financial Corp boosted its position in shares of Pfizer by 29,164.7% during the fourth quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock worth $415,878,000 after purchasing an additional 11,442,753 shares in the last quarter. Amundi Pioneer Asset Management Inc. boosted its position in shares of Pfizer by 81.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock worth $691,583,000 after purchasing an additional 8,563,358 shares in the last quarter. Charles Schwab Investment Advisory Inc. bought a new position in shares of Pfizer during the second quarter worth $286,229,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Pfizer by 11.9% during the fourth quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock worth $2,562,162,000 after purchasing an additional 7,534,957 shares in the last quarter. 69.04% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Story: Fundamental Analysis and Choosing Stocks

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.